Search

Displaying results 1441 - 1450 of 4233 in total
  1. Drug

    Pivhydrazine

    go.drugbank.com/drugs/DB09252
    ApprovedWithdrawn

    In 1960, it was widely used as an antidepressant agent but it is now discontinued. … Pivhydrazine, also known as pivazide, is a member of the hydrazine family with irreversible and non-selective inhibitory activity against monoamine oxidases.

  2. Drug

    Olsalazine

    go.drugbank.com/drugs/DB01250
    Approved

    Olsalazine is an aminosalicylate and a prodrug of mesalamine (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of sulfapyridine. Olsalazine comprises two mesalamine molecules jo...

  3. Drug

    Misoprostol

    go.drugbank.com/drugs/DB00929
    ApprovedInvestigational

    Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions. The stimulation of prostaglandin receptors in the stomach...

  4. Drug

    Ustekinumab

    go.drugbank.com/drugs/DB05679
    ApprovedInvestigational

    [A187346] The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and … Ustekinumab biosimilars are available in some markets, including Wezlana,[L49071] Yesintek,[L52815] Selarsdi,[L52820] Otulfi,[L52825] and Pyzchiva[L52810] in the US, Jamteki (AVT04),[L49076] Steqeyma,[

  5. Drug

    Lisocabtagene maraleucel

    go.drugbank.com/drugs/DB16582
    ApprovedInvestigational

    [L43322] In 2025, the FDA also approved lisocabtagene maraleucel as the first CAR T-cell therapy in the United States for adult patients with relapsed or refractory marginal zone lymphoma (MZL).

  6. Drug

    Doxecitine

    go.drugbank.com/drugs/DB02594
    ApprovedInvestigational

    Doxecitine is currently approved and marketed as a fixed-dose combination therapy with [thymidine] (KYGEVVI).

  7. Drug

    Milsaperidone

    go.drugbank.com/drugs/DB24348
    ApprovedInvestigational

    [A275426, A202004] Similarly, milsaperidone acts as an antagonist at dopamine D2 and 5-HT2A receptors,[A275427] as well as other adrenergic, dopamine, and serotonin receptor subtypes.

  8. Drug

    Opicapone

    go.drugbank.com/drugs/DB11632
    ApprovedInvestigational

    [L13772] It is marketed under the brand name Ongentys as once-daily oral capsules.

  9. Drug

    Cilazapril

    go.drugbank.com/drugs/DB01340
    ApprovedInvestigational

    It is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these varieties are available in the United States.

  10. Drug

    Carbazochrome

    go.drugbank.com/drugs/DB09012
    ApprovedWithdrawn

    It is not FDA-approved but is available as tablets or IM/SC injections in the treatment of hemorrhages in a number of countries.